Diabetes Mellitus as an Independent Risk Factor for Unfavorable Prognosis in Patients With Small Cell Lung Cancer.

IF 2.6 3区医学 Q3 ONCOLOGY

Thoracic Cancer Pub Date : 2026-08-01 DOI:10.1111/1759-7714.70378

Rui Yan, Patiguli Yisilamu, Yang Ge, Weiwei Zhou

{"title":"Diabetes Mellitus as an Independent Risk Factor for Unfavorable Prognosis in Patients With Small Cell Lung Cancer.","authors":"Rui Yan, Patiguli Yisilamu, Yang Ge, Weiwei Zhou","doi":"10.1111/1759-7714.70378","DOIUrl":null,"url":null,"abstract":"Background: Type 2 diabetes mellitus (DM) is implicated in cancer development and associated with poor survival in patients with cancer. However, the impact of DM on the outcome of small cell lung cancer (SCLC) remains unknown. This study investigated the correlation between DM and clinical outcomes and long-term prognosis of patients with extensive-stage small cell lung cancer (ES-SCLC).Methods: This retrospective cohort study was conducted using the medical records of patients with ES-SCLC treated with immune checkpoint inhibitors (ICIs) and chemotherapy. The demographic and clinical characteristics were retrospectively analyzed. Univariate and multivariate analyses were performed using Cox proportional hazards regression to evaluate the impact of the clinical characteristics on survival. Progression-free survival (PFS) and overall survival (OS) were compared between patients with or without DM.Results: Of the 91 patients with ES-SCLC, 32 were diagnosed with DM before ES-SCLC (35.2%). Patients with DM had significantly shorter median PFS (6 vs. 15 months, p = 0.026) and median OS (12 vs. 22 months, p = 0.013) than those without diabetes, despite receiving comparable chemoimmunotherapy. Multivariate cox regression analysis showed that DM was an independent risk factor for shorter mOS (HR 2.05, 95% CI 1.02-4.13, p = 0.044).Conclusions: Patients with ES-SCLC and comorbid diabetes exhibited significantly shorter OS and PFS compared with those without diabetes. DM serves as an independent adverse prognostic risk factor for ES-SCLC.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 16","pages":"e70378"},"PeriodicalIF":2.6000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13470881/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thoracic Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1759-7714.70378","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Type 2 diabetes mellitus (DM) is implicated in cancer development and associated with poor survival in patients with cancer. However, the impact of DM on the outcome of small cell lung cancer (SCLC) remains unknown. This study investigated the correlation between DM and clinical outcomes and long-term prognosis of patients with extensive-stage small cell lung cancer (ES-SCLC).

Methods: This retrospective cohort study was conducted using the medical records of patients with ES-SCLC treated with immune checkpoint inhibitors (ICIs) and chemotherapy. The demographic and clinical characteristics were retrospectively analyzed. Univariate and multivariate analyses were performed using Cox proportional hazards regression to evaluate the impact of the clinical characteristics on survival. Progression-free survival (PFS) and overall survival (OS) were compared between patients with or without DM.

Results: Of the 91 patients with ES-SCLC, 32 were diagnosed with DM before ES-SCLC (35.2%). Patients with DM had significantly shorter median PFS (6 vs. 15 months, p = 0.026) and median OS (12 vs. 22 months, p = 0.013) than those without diabetes, despite receiving comparable chemoimmunotherapy. Multivariate cox regression analysis showed that DM was an independent risk factor for shorter mOS (HR 2.05, 95% CI 1.02-4.13, p = 0.044).

Conclusions: Patients with ES-SCLC and comorbid diabetes exhibited significantly shorter OS and PFS compared with those without diabetes. DM serves as an independent adverse prognostic risk factor for ES-SCLC.

查看原文本刊更多论文

糖尿病是小细胞肺癌患者预后不良的独立危险因素。

背景：2型糖尿病（DM）与癌症的发展有关，并与癌症患者的低生存率相关。然而，糖尿病对小细胞肺癌（SCLC）预后的影响尚不清楚。本研究探讨了糖尿病与广泛期小细胞肺癌（ES-SCLC）患者临床结局和长期预后的相关性。方法：本回顾性队列研究使用免疫检查点抑制剂（ICIs）和化疗治疗的ES-SCLC患者的医疗记录进行。回顾性分析患者的人口学和临床特征。采用Cox比例风险回归进行单因素和多因素分析，评估临床特征对生存率的影响。结果：91例ES-SCLC患者中，32例在ES-SCLC之前被诊断为DM（35.2%）。尽管接受了相同的化学免疫治疗，但糖尿病患者的中位PFS（6个月vs 15个月，p = 0.026）和中位OS（12个月vs 22个月，p = 0.013）明显短于无糖尿病患者。多因素cox回归分析显示，DM是短寿命的独立危险因素（HR 2.05, 95% CI 1.02 ~ 4.13, p = 0.044）。结论：ES-SCLC合并糖尿病患者的OS和PFS明显短于无糖尿病患者。糖尿病是ES-SCLC的独立不良预后危险因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Thoracic Cancer ONCOLOGY-RESPIRATORY SYSTEM

CiteScore

5.20

自引率

3.40%

发文量

439

审稿时长

2 months

期刊介绍： Thoracic Cancer aims to facilitate international collaboration and exchange of comprehensive and cutting-edge information on basic, translational, and applied clinical research in lung cancer, esophageal cancer, mediastinal cancer, breast cancer and other thoracic malignancies. Prevention, treatment and research relevant to Asia-Pacific is a focus area, but submissions from all regions are welcomed. The editors encourage contributions relevant to prevention, general thoracic surgery, medical oncology, radiology, radiation medicine, pathology, basic cancer research, as well as epidemiological and translational studies in thoracic cancer. Thoracic Cancer is the official publication of the Chinese Society of Lung Cancer, International Chinese Society of Thoracic Surgery and is endorsed by the Korean Association for the Study of Lung Cancer and the Hong Kong Cancer Therapy Society. The Journal publishes a range of article types including: Editorials, Invited Reviews, Mini Reviews, Original Articles, Clinical Guidelines, Technological Notes, Imaging in thoracic cancer, Meeting Reports, Case Reports, Letters to the Editor, Commentaries, and Brief Reports.